1
|
Herrmann N, Nümm TJ, Iwamoto K, Leib N, Koch S, Majlesain Y, Maintz L, Kirins H, Schnautz S, Bieber T. Vitamin D 3-Induced Promotor Dissociation of PU.1 and YY1 Results in FcεRI Reduction on Dendritic Cells in Atopic Dermatitis. THE JOURNAL OF IMMUNOLOGY 2021; 206:531-539. [PMID: 33443066 DOI: 10.4049/jimmunol.2000667] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/18/2020] [Accepted: 11/23/2020] [Indexed: 12/12/2022]
Abstract
Atopic dermatitis (AD) is a severe inflammatory skin disease. Langerhans cells and inflammatory dendritic epidermal cells (IDEC) are located in the epidermis of AD patients and contribute to the inflammatory processes. Both express robustly the high-affinity receptor for IgE, FcεRI, and thereby sense allergens. A beneficial role of vitamin D3 in AD is discussed to be important especially in patients with allergic sensitization. We hypothesized that vitamin D3 impacts FcεRI expression and addressed this in human ex vivo skin, in vitro Langerhans cells, and IDEC models generated from primary human precursor cells. We show in this article that biologically active vitamin D3 [1,25(OH)2-D3] significantly downregulated FcεRI at the protein and mRNA levels of the receptor's α-chain, analyzed by flow cytometry and quantitative RT-PCR. We also describe the expression of a functional vitamin D receptor in IDEC. 1,25(OH)2-D3-mediated FcεRI reduction was direct and resulted in impaired activation of IDEC upon FcεRI engagement as monitored by CD83 expression. FcεRI regulation by 1,25(OH)2-D3 was independent of maturation and expression levels of microRNA-155 and PU.1 (as upstream regulatory axis of FcεRI) and transcription factors Elf-1 and YY1. However, 1,25(OH)2-D3 induced dissociation of PU.1 and YY1 from the FCER1A promotor, evaluated by chromatin immunoprecipitation. We show that vitamin D3 directly reduces FcεRI expression on dendritic cells by inhibiting transcription factor binding to its promotor and subsequently impairs IgE-mediated signaling. Thus, vitamin D3 as an individualized therapeutic supplement for those AD patients with allergic sensitization interferes with IgE-mediated inflammatory processes in AD patients.
Collapse
Affiliation(s)
- Nadine Herrmann
- Department of Dermatology and Allergy, University Hospital of Bonn, D-53127 Bonn, Germany; and .,Christine Kühne-Center for Allergy Research and Education, CH-7265 Davos, Switzerland
| | - Tim J Nümm
- Department of Dermatology and Allergy, University Hospital of Bonn, D-53127 Bonn, Germany; and.,Christine Kühne-Center for Allergy Research and Education, CH-7265 Davos, Switzerland
| | - Kazumasa Iwamoto
- Department of Dermatology and Allergy, University Hospital of Bonn, D-53127 Bonn, Germany; and
| | - Nicole Leib
- Department of Dermatology and Allergy, University Hospital of Bonn, D-53127 Bonn, Germany; and.,Christine Kühne-Center for Allergy Research and Education, CH-7265 Davos, Switzerland
| | - Susanne Koch
- Department of Dermatology and Allergy, University Hospital of Bonn, D-53127 Bonn, Germany; and
| | - Yasmin Majlesain
- Department of Dermatology and Allergy, University Hospital of Bonn, D-53127 Bonn, Germany; and
| | - Laura Maintz
- Department of Dermatology and Allergy, University Hospital of Bonn, D-53127 Bonn, Germany; and.,Christine Kühne-Center for Allergy Research and Education, CH-7265 Davos, Switzerland
| | - Helene Kirins
- Department of Dermatology and Allergy, University Hospital of Bonn, D-53127 Bonn, Germany; and
| | - Sylvia Schnautz
- Department of Dermatology and Allergy, University Hospital of Bonn, D-53127 Bonn, Germany; and
| | - Thomas Bieber
- Department of Dermatology and Allergy, University Hospital of Bonn, D-53127 Bonn, Germany; and.,Christine Kühne-Center for Allergy Research and Education, CH-7265 Davos, Switzerland
| |
Collapse
|
2
|
Herrmann N, Koch S, Leib N, Bedorf J, Wilms H, Schnautz S, Fimmers R, Bieber T. TLR2 down-regulates FcεRI and its transcription factor PU.1 in human Langerhans cells. Allergy 2013; 68:621-8. [PMID: 23534406 DOI: 10.1111/all.12145] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 02/11/2013] [Indexed: 01/31/2023]
Abstract
BACKGROUND Epidermal Langerhans cells (LC) expressing the high-affinity receptor for IgE (FcεRI) play a key role in atopic dermatitis (AD). AD skin is highly colonized with Staphylococcus aureus (S.a.), which are sensed by Toll-like receptor 2 (TLR2). We hypothesized that TLR2 may impact on the expression of FcεRI on LC. OBJECTIVES To study a putative impact of TLR2 signaling on FcεRI, we analyzed FcεRI and known transcription factors of the receptor after ligand binding to TLR2. METHODS We generated LC from CD34(+) progenitors in vitro (CD34LC) expressing FcεRI and TLR2 as well as its partners TLR1 and TLR6. The expression of FcεRI and known transcription factors of the receptor was analyzed on the protein and RNA level by flow cytometry, Western blotting, and real-time PCR. RESULTS For CD34LC from 123 donors, we observed a high heterogeneity in FcεRI surface expression correlating with mRNA level of its α-chain. Stimulation of TLR1/2 or TLR2/6 dramatically down-regulated FcεRI on protein and mRNA level of both α- and γ-chain. Further analysis of putative transcription factors for FCER1A revealed the lack of GATA1 in CD34LC, weak expression of ELF1 and YY1, and high expression of PU.1. While ELF1 and YY1 appeared to be little affected by TLR2 engagement, PU.1 was significantly down-regulated. CONCLUSIONS Taken together, our findings show that in human, LC ligation of TLR2 by S.a.-derived products down-regulates FcεRI and its transcription factor PU.1, thus suggesting that FcεRI is controlled by PU.1 in these cells.
Collapse
Affiliation(s)
- N. Herrmann
- Department of Dermatology and Allergy; University of Bonn; Bonn; Germany
| | - S. Koch
- Department of Dermatology and Allergy; University of Bonn; Bonn; Germany
| | - N. Leib
- Department of Dermatology and Allergy; University of Bonn; Bonn; Germany
| | - J. Bedorf
- Department of Pathology; University of Bonn; Bonn; Germany
| | - H. Wilms
- Department of Dermatology and Allergy; University of Bonn; Bonn; Germany
| | - S. Schnautz
- Department of Dermatology and Allergy; University of Bonn; Bonn; Germany
| | - R. Fimmers
- Institute for Medical Biometry, Informatics and Epidemiology; University of Bonn; Bonn; Germany
| | - T. Bieber
- Department of Dermatology and Allergy; University of Bonn; Bonn; Germany
| |
Collapse
|
3
|
Peng WM, Yu CF, Kolanus W, Mazzocca A, Bieber T, Kraft S, Novak N. Tetraspanins CD9 and CD81 are molecular partners of trimeric FcɛRI on human antigen-presenting cells. Allergy 2011; 66:605-11. [PMID: 21241315 DOI: 10.1111/j.1398-9995.2010.02524.x] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
Abstract
BACKGROUND Most functions of tetraspanins are not related to cell-surface receptor ligand binding, but are mediated by direct interactions with their partner proteins. Functions of trimeric FcɛRI, expressed by antigen-presenting cells (APCs), range from amplification of allergic inflammatory reactions to their active suppression. Cell-type-specific protein-protein interactions might play a role in the regulation of these bidirectional tasks. Therefore, we intended to study the interactions of trimeric FcɛRI with tetraspanins. METHODS The expression levels of tetraspanins CD9, CD37, CD53, CD63, CD81, CD82, and CD151 on skin dendritic cells of atopic dermatitis (AD) patients or healthy individuals were detected by flow cytometry. Tetraspanin expression on FcɛRI(pos) and FcɛRI(neg) monocyte subpopulations was evaluated. Flow cytometry, confocal microscopy, immunoprecipitation, and immunoblotting experiments were performed to observe the relationship between tetraspanins CD9 and CD81 and FcɛRI. Furthermore, plate stimulation experiments were performed, and cytokines in the supernatants were detected. RESULTS We found that human FcɛRI(pos) APCs expressed high amounts of tetraspanins and that the tetraspanins CD9 and CD81 were associated with FcɛRI. Concomitant activation of FcɛRI and CD9 on human monocytes increased FcɛRI-mediated cytokine release. CONCLUSION Taken together, we show for the first time that CD9 and CD81 act as molecular partners of trimeric FcɛRI on human APC, which might be of importance in allergic diseases such as AD.
Collapse
Affiliation(s)
- W M Peng
- Department of Dermatology and Allergy, University of Bonn Medical, Bonn, Germany
| | | | | | | | | | | | | |
Collapse
|
4
|
Donnelly RF, McCarron PA, Morrow DIJ, Sibani SA, Woolfson AD. Photosensitiser delivery for photodynamic therapy. Part 1: Topical carrier platforms. Expert Opin Drug Deliv 2008; 5:757-66. [PMID: 18590460 DOI: 10.1517/17425247.5.7.757] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
Abstract
BACKGROUND Photodynamic therapy (PDT) is a medical treatment in which a combination of a photosensitising drug and visible light causes destruction of selected cells. Due to the lack of true selectivity of preformed photosensitisers for neoplastic tissue and their high molecular weights, PDT of superficial skin lesions has traditionally been mediated by topical application of the porphyrin precursor 5-aminolevulinic acid (ALA). OBJECTIVE This article aims to review the traditional formulation-based approaches taken to topical delivery of ALA and discusses the more innovative strategies investigated for enhancement of PDT mediated by topical application of ALA and preformed photosensitisers. METHODS All of the available published print and online literature in this area was reviewed. As drug delivery of agents used in PDT is still something of an emerging field, it was not necessary to go beyond literature from the last 30 years. RESULTS/CONCLUSION PDT of neoplastic skin lesions is currently based almost exclusively on topical application of simple semisolid dosage forms containing ALA or its methyl ester. Until expiry of patents on the current market-leading products, there is unlikely to be a great incentive to engage in design and evaluation of innovative formulations for topical PDT, especially those containing the more difficult-to-deliver preformed photosensitisers.
Collapse
Affiliation(s)
- Ryan F Donnelly
- School of Pharmacy, Medical Biology Centre, Queen's University Belfast, 97 Lisburn Road, Belfast, UK.
| | | | | | | | | |
Collapse
|
5
|
Donnelly RF, McCarron PA, Woolfson DA. Derivatives of 5-Aminolevulinic Acid for Photodynamic Therapy. PERSPECTIVES IN MEDICINAL CHEMISTRY 2007. [DOI: 10.1177/1177391x0700100005] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
Photodynamic therapy (PDT) is a clinical treatment that combines the effects of visible light irradiation with subsequent biochemical events that arise from the presence of a photosensitising drug (possessing no dark toxicity) to cause destruction of selected cells. Today, the most common agent used in dermatological PDT is 5-aminolevulinic acid (ALA). As a result of its hydrophilic character, ALA penetrates skin lesions poorly when applied topically. Its systemic bioavailability is limited and it is known to cause significant side effects when given orally or intravenously. Numerous chemical derivatives of ALA have been synthesised with the aims of either improving topical penetration or enhancing systemic bioavailability, while reducing side effects. In vitro cell culture experiments with ALA derivatives have yielded promising results. However, if ALA derivatives are to demonstrate meaningful clinical benefits, a rational approach to topical formulation design is required, along with a systematic study aimed at uncovering the true potential of ALA derivatives in photodynamic therapy. With respect to systemic ALA delivery, more study is required in the developing area of ALA-containing dendrons and dendrimers.
Collapse
Affiliation(s)
- Ryan F. Donnelly
- School of Pharmacy, Queen's University Belfast, Medical Biology Centre, 97 Lisburn Road, Belfast BT9 7BL, U.K
| | - Paul A. McCarron
- School of Pharmacy, Queen's University Belfast, Medical Biology Centre, 97 Lisburn Road, Belfast BT9 7BL, U.K
| | - David A. Woolfson
- School of Pharmacy, Queen's University Belfast, Medical Biology Centre, 97 Lisburn Road, Belfast BT9 7BL, U.K
| |
Collapse
|
6
|
Abstract
The type I Fc epsilon receptor (Fc epsilon RI) is one of the better understood members of its class and is central to the immunological activation of mast cells and basophils, the key players in immunoglobulin E (IgE)-dependent immediate hypersensitivity. This review provides background information on several distinct regulatory mechanisms controlling this receptor's stimulus-response coupling network. First, we review the current understanding of this network's operation, and then we focus on the inhibitory regulatory mechanisms. In particular, we discuss the different known cytosolic molecules (e.g. kinases, phosphatases, and adapters) as well as cell membrane proteins involved in negatively regulating the Fc epsilon RI-induced secretory responses. Knowledge of this field is developing at a fast rate, as new proteins endowed with regulatory functions are still being discovered. Our understanding of the complex networks by which these proteins exert regulation is limited. Although the scope of this review does not include addressing several important biochemical and biophysical aspects of the regulatory mechanisms, it does provide general insights into a central field in immunology.
Collapse
Affiliation(s)
- Jakub Abramson
- Department of Immunology, The Weizmann Institute of Science, Rehovot, Israel
| | | |
Collapse
|
7
|
Kraft S, Kinet JP. New developments in FcepsilonRI regulation, function and inhibition. Nat Rev Immunol 2007; 7:365-78. [PMID: 17438574 DOI: 10.1038/nri2072] [Citation(s) in RCA: 414] [Impact Index Per Article: 24.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/13/2023]
Abstract
The high-affinity Fc receptor for IgE (FcepsilonRI), a multimeric immune receptor, is a crucial structure for IgE-mediated allergic reactions. In recent years, advances have been made in several important areas of the study of FcepsilonRI. The first area relates to FcepsilonRI-mediated biological responses that are antigen independent. The second area encompasses the biological relevance of the distinct signalling pathways that are activated by FcepsilonRI; and the third area relates to the accumulated evidence for the tight control of FcepsilonRI signalling through a broad array of inhibitory mechanisms, which are being developed into promising therapeutic approaches.
Collapse
Affiliation(s)
- Stefan Kraft
- Laboratory of Allergy and Immunology, Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Institutes of Medicine 945, 71 Avenue Louis Pasteur, Boston, Massachusetts 02215, USA
| | | |
Collapse
|
8
|
Bieber T. The pro- and anti-inflammatory properties of human antigen-presenting cells expressing the high affinity receptor for IgE (FcεRI). Immunobiology 2007; 212:499-503. [PMID: 17544834 DOI: 10.1016/j.imbio.2007.03.001] [Citation(s) in RCA: 50] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/01/2007] [Accepted: 03/01/2007] [Indexed: 11/18/2022]
Abstract
Almost 20 years after the first description of IgE on the surface of epidermal Langerhans cells (LC) and the subsequent characterization of the trimeric Fc epsilon RI on human antigen-presenting cells (APC), we have gained profound insights into the receptor responsible for this binding. Fc epsilon RI may act as a pro-inflammatory structure on some APC such as inflammatory dendritic epidermal cells (IDEC) in the skin of patients with atopic dermatitis while it can also be an important instrument in mechanisms leading to tolerance on other APC such as LC of the oral mucosa. By virtue of Fc epsilon RI, APC can initiate inflammation by secretion of a wide spectrum of pro-inflammatory cytokines and chemokines. Fc epsilon RI+DC can induce either Th2 or Th1 profile in T-cells. In contrast, the production of the tryptophan-catabolizing enzyme indoleamine 2,3-dioxygenase (IDO) as well as IL-10 and TGFss may contribute to the tolerogenic properties of DC.
Collapse
Affiliation(s)
- Thomas Bieber
- Department of Dermatology and Allergy, University of Bonn, Sigmund-Freud-Street 25, 53105 Bonn, Germany.
| |
Collapse
|
9
|
Novak N, Bieber T, Kraft S. Immunoglobulin E-bearing antigen-presenting cells in atopic dermatitis. Curr Allergy Asthma Rep 2005; 4:263-9. [PMID: 15175139 DOI: 10.1007/s11882-004-0069-2] [Citation(s) in RCA: 43] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
Abstract
Human antigen-presenting cells (APCs) bind monomeric immunoglobulin E (IgE) via the high-affinity IgE receptor, Fc epsilon RI. Surface expression of this trimeric structure is strongly associated with the atopic status of the donors, and maximal levels are observed on Langerhans cells (LC) and inflammatory dendritic epidermal cells (IDEC) in atopic dermatitis (AD). Although intracellular expression of the Fc epsilon RI alpha-chain is induced by interleukin-4 (IL-4), the upregulation of surface levels on dendritic cells (DC) from atopics is due to enhanced expression of the Fc epsilon RI gamma-chain and stabilization by binding of its ligand IgE. A characteristic function of Fc epsilon RI-bearing APCs is the specific uptake and processing of IgE-bound allergens, which is followed by T-cell stimulation. In AD, DC-mediated presentation of aeroallergens penetrating the epidermis is thought to induce an IgE-mediated, delayed-type hypersensitivity reaction. In addition, different Fc epsilon RI-bearing APC subsets in AD skin might regulate inflammatory processes through the production of Th1/Th2-polarizing signals, proinflammatory cytokines, chemokines, and factors that are involved in the induction of tolerance.
Collapse
Affiliation(s)
- Natalija Novak
- Division of Allergy and Immunology, Department of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School, 330 Brookline Avenue, Boston, MA 02215, USA
| | | | | |
Collapse
|
10
|
Donnelly RF, McCarron PA, Woolfson AD. Drug Delivery of Aminolevulinic Acid from Topical Formulations Intended for Photodynamic Therapy¶. Photochem Photobiol 2005. [DOI: 10.1562/2004-08-23-ir-283r1.1] [Citation(s) in RCA: 45] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
|
11
|
von Bubnoff D, Scheler M, Hinz T, Matz H, Koch S, Bieber T. Comparative immunophenotyping of monocytes from symptomatic and asymptomatic atopic individuals. Allergy 2004; 59:933-9. [PMID: 15291900 DOI: 10.1111/j.1398-9995.2004.00546.x] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
BACKGROUND Allergy has at least two components - a genetic predisposition referred to as atopy and the progress from an atopic state to clinically apparent disease. Peripheral blood monocytes are circulating myeloid precursors of antigen-presenting cells. The expression of cell surface proteins on monocytes may therefore witness the disease status and affect the development of allergic disease. METHODS Monocytes were isolated from atopic individuals with seasonal allergic rhinitis (n = 10), from atopic individuals sensitized to aeroallergens but without any signs of acute disease (n = 11), and from healthy nonatopic donors (n = 21). Detailed comparative phenotypic analysis of CD14(+) and FcepsilonRI(+)CD14(+) monocytes was performed by flow cytometry. RESULTS CD14(+) monocytes from symptomatic atopic donors showed a significant increase in the cell surface intensity of the integrin adhesion molecule CD11c over monocytes from asymptomatic atopic and nonatopic donors. Asymptomatic atopic individuals showed significantly enhanced expression of FcepsilonRI on the CD14(high)CD16(dim) monocyte subset compared with this subset from symptomatic atopic and nonatopic donors. CONCLUSION The increase in monocyte surface intensity of the adhesion molecule CD11c may be involved in the manifestation of allergic disease. FcepsilonRI on CD14(high)CD16(dim) monocytes of asymptomatic atopic donors may be of functional importance for the maintenance of clinical unresponsiveness toward allergens.
Collapse
Affiliation(s)
- D von Bubnoff
- Department of Dermatology, University of Bonn, Bonn, Germany
| | | | | | | | | | | |
Collapse
|
12
|
von Bubnoff D, Bausinger H, Matz H, Koch S, Häcker G, Takikawa O, Bieber T, Hanau D, de la Salle H. Human Epidermal Langerhans Cells Express the Immunoregulatory Enzyme Indoleamine 2,3-Dioxygenase. J Invest Dermatol 2004; 123:298-304. [PMID: 15245429 DOI: 10.1111/j.0022-202x.2004.23217.x] [Citation(s) in RCA: 47] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
Abstract
Langerhans cells (LC) are a special subset of dendritic cells integrating cutaneous immunity. The study of LC function is of major interest not only for efforts of vaccine design and immunotherapy but also for gaining an insight into the pathogenesis of immune-mediated cutaneous diseases and neoplasias. Recently, defined antigen-presenting cells were described that express indoleamine 2,3-dioxygenase (IDO) and inhibit T cell proliferation in vitro and in vivo. Here, we show that stimulation with interferon-gamma (IFN-gamma) induces the expression of functionally active IDO in highly purified human epidermal LC. The induction of IDO after stimulation of LC with IFN-gamma seems to follow a defined kinetic with rapid upregulation followed by a downregulation after about 24 h of culture. Accordingly, proliferation of T cells induced by anti-CD3 antibodies was modulated by supernatants of IFN-gamma-activated human epidermal LC. Importantly, downregulation of T cell proliferation by supernatants of 24 h IFN-gamma-activated LC was prevented by inhibition of IDO. These results indicate that LC not only have the capacity to stimulate but also to inhibit T cells, and suggest that LC possess an immunoregulatory function in promoting T cell tolerance by production of IDO.
Collapse
Affiliation(s)
- Dagmar von Bubnoff
- Department of Dermatology, Friedrich-Wilhelms University, Bonn, Germany.
| | | | | | | | | | | | | | | | | |
Collapse
|
13
|
Becker Y. Vaccinia virus pathogenicity in atopic dermatitis is caused by allergen-induced immune response that prevents the antiviral cellular and humoral immunity. Virus Genes 2004; 27:269-82. [PMID: 14618088 DOI: 10.1023/a:1026399916888] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Abstract
Atopic dermatitis (AD) serves as a contraindication for the immunization of AD patients with a live vaccinia virus (VV) vaccine. The antiallergen IgE interacts with the Fc receptors (FcepsilonRI) on dendritic cell (DC) membranes and with allergen molecules. The immunological events that lead to AD disease, the activation of the T-helper 2 (Th2) immune response, the synthesis of the cytokines IL-4, IL-5, IL-13, and the inhibition of the T-helper 1 (Th1) damage the capacity of the host to develop anti-VV cytotoxic cells (CTLs). In the presence of Th2-derived cytokine IL-4 in the AD skin and the synthesis of VV proteins that interfere recruitment of DCs by host cytokines, the VV can cause a generalized infection. Conceptually, new VV recombinants may be needed for human immunization. Such VV recombinants should lack the genes that interfere with the host immune system and express a mutated human IL-4 cytokine gene that will prevent negative regulatory mechanisms. Such improved VV recombinants may be used to express genes from pathogenic viruses.
Collapse
Affiliation(s)
- Yechiel Becker
- Department of Molecular Virology, Faculty of Medicine, The Hebrew University of Jerusalem, P.O.B. 12272, Jerusalem 91120, Israel.
| |
Collapse
|
14
|
Abstract
PURPOSE OF REVIEW The manifestation of atopic eczema/dermatitis syndrome is believed to result from a complex interrelationship of environmental factors, pharmacological abnormalities, skin barrier defects, and immunological phenomena. Although we are only beginning to understand the molecular basis of this disease, much progress has been made in defining key events leading to the manifestation of allergic inflammation. Here, we review recent findings that underscore the importance of dendritic cells as being central to shape these proinflammatory responses. RECENT FINDINGS Evidence for a differential regulation of the high affinity receptor for IgE, Fc epsilon RI, on the surface of atopic dendritic cells compared with non-atopic dendritic cells became apparent. In atopic donors, in contrast to non-atopic donors, the intracellular expression of the gamma-chains of Fc epsilon RI is sufficient, thus leading to the assembly with the alpha-chain and surface expression of the receptor. This finding is of considerable interest for an understanding of the pathophysiology of IgE-mediated dendritic cell functions in atopic eczema/dermatitis syndrome. In addition, it has been shown that keratinocytes from the epidermal skin of individuals with atopic eczema/dermatitis syndrome express human thymic stromal lymphopoietin, which activates dendritic cells to attract T helper type 2 cells into the skin. Furthermore, these activated dendritic cells prime naïve T cells into T helper type 2 cells. SUMMARY The past few years have seen a remarkable process of refocusing in atopy. Dendritic cells in particular have been at the centre of this process. It has become unequivocally clear that these cells have the power of shaping the allergic response.
Collapse
|
15
|
Novak N, Kraft S, Bieber T. Unraveling the mission of FcepsilonRI on antigen-presenting cells. J Allergy Clin Immunol 2003; 111:38-44. [PMID: 12532094 DOI: 10.1067/mai.2003.2] [Citation(s) in RCA: 81] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/08/2023]
Abstract
A decade ago, the discovery of the high-affinity receptor for IgE (FcepsilonRI) on epidermal Langerhans cells documented the end of the dogma that FcepsilonRI is only expressed on effector cells of anaphylaxis. Since then, the functional significance of this receptor on antigen-presenting cells (APCs) has been an area of intense research work. Scientists have focused on a better understanding of the molecular structure, regulation, and role of FcepsilonRI on APCs in the human immune system. Insights into the cellular events linked to the activation of APCs on ligation of FcepsilonRI by IgE and allergens might provide the basis for new aspects in the pathophysiology of allergic diseases and the design of future diagnostic and therapeutic strategies. This review is dedicated to the 10th anniversary of the discovery of FcepsilonRI on APCs and describes the numerous areas of research in this field.
Collapse
Affiliation(s)
- Natalija Novak
- Department of Dermatology, Rheinische-Friedrich-Wilhelms-University of Bonn, Bonn, Germany
| | | | | |
Collapse
|